Sun Pharma net profit up 43 percent at Rs 2,061 crore in Q1

Specialty business grew 29 per cent driven by Ilumya, Cequa, Odomzo and Winlevi, he added.

Published On 2022-07-29 12:01 GMT   |   Update On 2022-07-29 12:01 GMT
Advertisement

New Delhi: Sun Pharma on Friday reported 43 percent rise in consolidated net profit at Rs 2,061 crore for June quarter, riding on robust sales across markets.

The Mumbai-based company had posted a net profit of Rs 1,444 crore in April-June 2021-22.

Total revenue from operations rose to Rs 10,762 crore in the period under review from Rs 9,719 crore earlier, Sun Pharmaceutical Industries said in a regulatory filing.

"For Q1, all our businesses recorded good growth, driven by a combination of sustained scale-up for our specialty business and all-round growth across markets," Managing Director Dilip Shanghvi said.

Specialty business grew 29 per cent driven by Ilumya, Cequa, Odomzo and Winlevi, he added.

Read also: Sun Pharma plans to increase field force in India by 10 percent in current fiscal

"Our India business continues to grow faster than market, leading to increase in market share. We have been able to report healthy margins despite rising costs," Shanghvi said.

The company continues to focus on expanding global specialty business, growing all its businesses and improving market share, he added.

Shares of the company were trading 3.88 per cent up at Rs 929.5 apiece on the BSE.

Read also: Sun Pharma to commercialise acne cream WINLEVI in Japan, Russia and 4 other territories

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates.

Read also: Sun Pharma expects high single-digit top-line growth in FY23

Tags:    
Article Source : with inputs

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News